Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Endometrial Neoplasms × talazoparib × Clear all

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Triple Negative Breast Neoplasms 3 Neuroectodermal Tumors, Primitive, Peripheral 2 Leukemia, Myeloid, Acute 2 Carcinoma, Renal Cell 2 Wilms Tumor 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Prostatic Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Kidney Neoplasms 1 Hepatoblastoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumor 1 Advanced Ovarian Cancer 1

Interventions

pembrolizumab 14 Carboplatin 10 Paclitaxel 6 Nivolumab 6 Bevacizumab 5 Fulvestrant 4 olaparib 3 lenvatinib 3 PM 01183 3 Letrozole 3 AZD5305 3 toripalimab 2 tisotumab vedotin 2 spartalizumab 2 sarilumab 2 sargramostim 2 sacituzumab govitecan 2 ribociclib 2 palbociclib 2 epacadostat 2 enzalutamide 2 dostarlimab 2 cemiplimab 2 anlotinib 2 abemaciclib 2 X-Rays 2 Specimen Handling 2 Pemetrexed 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04486352 2025-09-04

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡